CytomX Shares Rise After Trial Progress CytomX (CTMX) drew analyst attention on Mar 27, 2026 after progress in a Phase 1 program; institutional investors should watch upcoming readouts and funding runway closely.

CytomX Shares Rise After Trial Progress: CytomX (CTMX) drew analyst attention on Mar 27, 2026 after progress in a Phase 1 program; institutional investors should watch upcoming readouts and funding runway closely. 👈 Read full analysis #CytomX #CTMX #Pharmaceuticals #Investing #ClinicalTrials

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten public offering of 45,990,567 shares of its common stock at a price to the

#CTMX CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/CTMX/cytom-x-therap...

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants CytomX Therapeutics (NASDAQ:CTMX) has commenced an underwritten public offering of $250.0 million of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $37.5 million. The offering is subject to market and other conditions and may not be completed.According to the company, net proceeds are expected to fund continued development of Varseta-M and other pipeline programs, with any remaining proceeds for capital expenditures, working capital and general corporate purposes. A shelf registration filed March 16, 2026, became effective upon filing.

#CTMX CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/CTMX/cytom-x-therap...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#OCUL, #IONQ, #SOGP, #SBET, #CTMX

#OptionFlow #OptionsTrading #Trading

CytomX Therapeutics Announces Business Update and Company Milestones for 2026 CytomX (NASDAQ: CTMX) provided a 2026 business update focused on clinical milestones for its PROBODY pipeline. Varsetatug masetecan (CX-2051) Phase 1 dose expansions (7.2, 8.6, 10 mg/kg Q3W) continue, with total Phase 1 enrollment projected at ~100 patients and a Phase 1 CRC expansion update expected in Q1 2026. The company aims to align with the FDA in 2026 on a potential registrational monotherapy study and plans a Varseta-M plus bevacizumab combination study to start in Q1 2026.CX-801 (masked interferon-alpha-2b) is in Phase 1 for advanced melanoma; monotherapy reached dose level 4 and combination dose escalation with KEYTRUDA began in May 2025, with initial combo data expected by end of 2026. Management will present at JP Morgan on January 14, 2026.

#CTMX CytomX Therapeutics Announces Business Update and Company Milestones for 2026

www.stocktitan.net/news/CTMX/cytom-x-therap...

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update CytomX Therapeutics (Nasdaq: CTMX) reported Q3 2025 results and a pipeline update on Nov 6, 2025. The company ended Q3 with $143.6 million in cash, cash equivalents and investments and expects runway to Q2 2027. Q3 revenue was $6.0 million versus $33.4 million a year earlier, driven by completion of Bristol Myers Squibb performance obligations and reduced Moderna activity. Operating expense for the quarter was $21.7 million and R&D was $15.3 million.Pipeline highlights: CX-2051 Phase 1 expansion is ongoing, with projected enrollment of ~100 patients by a planned Phase 1 data update in Q1 2026; a CX-2051 Phase 1b combination with bevacizumab is expected to start in Q1 2026. CX-801 monotherapy biomarker data will be presented at SITC 2025 and supports ongoing combination dosing with KEYTRUDA; combo escalation began in May 2025.

#CTMX CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTMX/cytom-x-therap...

CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 CytomX reports Grade 5 adverse event in colorectal cancer drug study but safety committee supports trial continuation. 73 patients enrolled across three dose levels. See updates.

#CTMX CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

www.stocktitan.net/news/CTMX/cytom-x-therap...

CytomX Earnings: Breakthrough Colorectal Cancer Drug Shows Promise as Company Raises $100M CytomX advances colorectal cancer treatment CX-2051 with promising Phase 1 data. $158M cash position extends runway to 2027. See full trial results.

#CTMX CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTMX/cytom-x-therap...

Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study First patient receives CytomX's masked interferon CX-801 with Keytruda in Phase 1 melanoma trial. Biomarker data expected H2 2025. See trial details.

#CTMX CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

www.stocktitan.net/news/CTMX/cytom-x-therap...

CytomX ($CTMX) stock soared 280% after promising Phase 1 results for its cancer therapy, CX-2051, and a $93.4M stock offering. Is this the start of a biotech resurgence?

Full analysis ⬇️
www.valuethemarkets.com/analysis/cyt...

#CTMX #BiotechStocks #CancerResearch #Investing #ValueTheMarkets

JUST IN: ( NASDAQ: #CTMX ) CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock CytomX Therapeutics (NASDAQ:CTMX) has announced the pricing of an underwritten public offering of 76,923,076 shares of common stock at $1.30 per share, aiming to raise approximately $100 million in gross proceeds. The offering, expected to close on May 13, 2025, features participation from notable investors including Longitude Capital, OrbiMed, Venrock Healthcare Capital Partners, Vivo Capital, and RTW Investments.The company plans to use the proceeds for research and development, general corporate purposes, and working capital needs. Jefferies and Piper Sandler are serving as joint book-running managers for the offering, which is being conducted through an effective shelf registration statement filed with the SEC.

#CTMX CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

www.stocktitan.net/news/CTMX/cytom-x-therap...

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) in Patients with Advanced Colorectal Cancer (CRC) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses. Additional CX-2051 Phase 1 data update

#CTMX CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTMX/cytom-x-therap...

Revolutionary Cancer Treatment Breakthrough: CytomX and Moderna's New mRNA Therapy Shows Promise with Reduced Toxicity New mRNA-encoded masked IL-12 shows powerful anti-tumor effects with enhanced safety profile. CytomX-Moderna collaboration delivers promising preclinical results. Learn more.

#CTMX CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

www.stocktitan.net/news/CTMX/cytom-x-therap...

Can CytomX's 36% Revenue Surge Fund Its Next-Gen Cancer Drug Breakthrough? Revenue jumps to $138.1M as CytomX streamlines operations and advances EpCAM-targeting cancer drug. $100M cash position supports development through 2026.

#CTMX CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/CTMX/cytom-x-therap...

CytomX Slashes 40% of Workforce, Prioritizes Cancer Drug Pipeline in Strategic Overhaul Biotech firm CytomX restructures operations, cutting 40% of staff while focusing on CX-2051 cancer therapy program. Cash runway extended to Q2 2026 with $117.6M in reserves.

#CTMX CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

www.stocktitan.net/news/CTMX/cytom-x-therap...

#CTMX CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

www.stocktitan.net/news/CTMX/cytom-x-therap...

CytomX Therapeutics, Inc.($CTMX) High Capital Efficiency, Uncertain Earnings for Value Traders?

open.substack.com/pub/tgsmnews... #CTMX

BREAKING NEWS: ( NASDAQ: #CTMX ) CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY , in a Phase 1 Study in Patients with Solid Tumors

#StockMarket #News

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#HUMA, #CTMX, #ONON, #RBLX, #ALT

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #HUMA 62% OTM
2. #ALCC 36% OTM
3. #CTMX 30% OTM
4. #RBLX 22% OTM
5. #ONON 22% OTM

#OptionFlow #OptionsTrading #Trading

Breaking on The Street Stocks To Watch Now! CTMX, PRSO, IMCC, KAVL, VTAK Getting your Trinity Audio player ready... Investors are eyeing numerous companies lately, and here’s an insight into five of them. CytomX Therapeutics Inc. (NASDAQ: CTMX), a key player in conditional...

Eyes On The Street
#CTMX, #PRSO, #IMCC, #KAVL, #VTAK
thestreetreports.com/breaking-on-...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#TGTX, #SYF, #CTMX, #NCLH, #MTCH

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#TGTX, #CTMX, #MTCH, #DBRG, #LSEA

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NYCB 14.5x
2. #TGTX 8.6x
3. #CTMX 5.2x
4. #MTCH 4.5x
5. #SBUX 4.4x

#OptionFlow #OptionsTrading #Trading